Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TCR-NK
- Development stage
- Preclinical
- Lead developer
- ImmuXell
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TCR-NK is an investigational allogeneic natural killer (NK) cell therapy being developed by ImmuXell. It consists of donor-derived NK cells engineered to express a T cell receptor (TCR) or TCR-like molecule specific for KRAS-derived antigens. This platform leverages the potent, MHC-independent cytotoxic activity of NK cells while providing them with the high-specificity targeting of a TCR. A key advantage of using NK cells over T cells for TCR engineering is the absence of endogenous TCR chains, which eliminates the risk of TCR mispairing and the formation of potentially autoreactive receptors. The therapy is designed to treat solid tumors and other cancers harboring KRAS mutations and is currently in the IND-enabling phase of development.
- Other names
- TCR-NK cell therapyallogeneic TCR-NK cell therapyImmuXell TCR-NK
02
Targets
MHC I (MHC class I})
Beyond the preview
Go deeper on TCR-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCR-NK.